New Horizons in COPD Treatment: What Patients Should Know According to GOLD 2023
- Health Communicator
- Jun 22
- 6 min read
Updated: Jul 10
This article summarizes the most important and up-to-date information for patients with chronic obstructive pulmonary disease (COPD), based entirely on the peer-reviewed scientific publication "The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD," published in the journal Pulmonary Therapy in 2023. The authors of this publication are Dr. Paul D. Terry and Dr. Rajiv Dhand—respected medical professionals, educators, and clinicians from the Graduate School of Medicine at the University of Tennessee Medical Center, USA, with extensive experience in the research and treatment of pulmonary diseases. Their article analyzes and explains the latest recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), with a focus on inhaled pharmacological therapy and how it should be applied according to the individual needs of patients. The following questions and answers are formulated to be as helpful as possible to patients and their loved ones, and are based solely on the content of this scientific publication.
“Adherence to inhaled COPD medications is generally low (<50%), despite its clear importance for symptom and exacerbation control, reducing healthcare use and costs, and improved survival and quality of life.”
